Coagulation in familial hypercholesterolemic patients: effect of current hypolipidemic treatment and anticoagulants
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10499659" target="_blank" >RIV/00179906:_____/25:10499659 - isvavai.cz</a>
Alternative codes found
RIV/60162694:G44__/26:00564445 RIV/00216208:11150/25:10499659 RIV/00216208:11160/25:10499659
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=6eLb8QoBLQ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=6eLb8QoBLQ</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00210-024-03740-1" target="_blank" >10.1007/s00210-024-03740-1</a>
Alternative languages
Result language
angličtina
Original language name
Coagulation in familial hypercholesterolemic patients: effect of current hypolipidemic treatment and anticoagulants
Original language description
Familial hypercholesterolemia (FH) is a relatively rare genetic disease associated with high serum cholesterol levels but also with abnormalities in blood coagulation. Novel pharmacotherapeutic approaches in FH including proprotein convertase subtilisin/kexin type 9 antibodies (PCSK9Ab) are very efficient in decreasing cholesterol levels but their impact on coagulation in FH is not yet established. Therefore, we hypothesized that these novel antidyslipidemic drugs can positively impact blood coagulation due to their more potent effect on cholesterol. A total of 15 healthy volunteers and all 15 available patients with severe FH treated at the University Hospital Hradec Králové were enrolled, coagulation was assessed by mechanic coagulometer, and the impact of four clinically used direct anticoagulants was analyzed ex vivo. FH patients were treated effectively as their total cholesterol was 4.11 +/- 1.57 mM and LDL cholesterol was 2.44 +/- 1.46 mM, which were even lower values than detected in our generally healthy controls. Twelve from the 15 FH patients were finally analyzed as 3 were treated with anticoagulants. Coagulation in FH patients was prolonged more extensively by dabigatran and rivaroxaban, when compared to healthy controls. Treatment with PCSK9Ab or lipid apheresis did not seem to have a significant effect on coagulation. The latter procedure however significantly decreased serum levels of one vitamin K form, MK4. Shorter coagulation time was associated with higher levels of LDL, non-HDL, and total cholesterol. Current treatment of FH seems to improve the effects of direct anticoagulants beyond known effects on LDL cholesterol levels.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
<a href="/en/project/NU21J-02-00021" target="_blank" >NU21J-02-00021: Differences in parameters of platelets aggregation and blood coagulation between healthy individuals and patients with metabolic diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Naunyn-Schmiedeberg's Archives of Pharmacology
ISSN
0028-1298
e-ISSN
1432-1912
Volume of the periodical
398
Issue of the periodical within the volume
6
Country of publishing house
DE - GERMANY
Number of pages
10
Pages from-to
7343-7352
UT code for WoS article
001388914600001
EID of the result in the Scopus database
2-s2.0-85213950846